Navigation Links
UCSF Helen Diller Cancer Center awarded $36 million grant

The National Cancer Institute has awarded the UCSF Helen Diller Family Comprehensive Cancer Center a $36 million grant to fund cutting edge research programs and clinical trials over five years.

The highly competitive funding, awarded in recognition of UCSF's excellence in laboratory, clinical and population-based research, will fund administrative management and infrastructure to support efforts across the spectrum of cancers, including breast cancer, prostate cancer and pediatric cancer.

The grant is the latest funding to the center, which is one of the country's leading cancer and clinical care programs, and is the only comprehensive cancer center in the San Francisco Bay Area.

The first year's award amounts to $7.2 million. The balance of the award was recommended by the National Institutes of Health subject to the availability of funds and satisfactory progress toward the goals of the center.

"We are pleased that the National Cancer Institute has recognized the work of our cancer center and has continued to make financing cancer research a high priority," said Frank McCormick, PhD, who has served as director of the UCSF Helen Diller Family Comprehensive Cancer Center since 1997.

"Cancer is a devastating disease that takes the life of an American every minute of every day," said McCormick, who is president of the American Association for Cancer Research, a member of the Institute of Medicine, and a Fellow of the Royal Society as well as a scientist actively engaged in cancer research. "Federal support for cancer research is imperative as we move forward with research to save lives in our generation and for future generations."

The Helen Diller Family Comprehensive Cancer Center received the fifth largest amount of funding for its cancer support grant last year among the 67 NCI-designated cancer centers in the United States, according to NCI statistics.

UCSF received the comprehensive cancer center designation in 1999. The NCI awards the comprehensive designation after a rigorous evaluation process demonstrating breadth of research in laboratory, clinical, and population-based research, as well as substantial interdisciplinary research that bridges these scientific areas.

"The NCI-designated cancer centers program recognizes centers around the country that meet rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research," said Linda K. Weiss, PhD, director of the Office of Cancer Centers of the National Cancer Institute. "These centers including the UCSF Helen Diller Family Comprehensive Cancer Center have dedicated significant resources into developing research programs, faculty and facilities that will lead to better approaches to prevention, diagnosis, and treatment of cancer. The NCI designation not only recognizes excellence but opens doors to greater federal funding, information sharing, and resources."

In the NCI's award notification that touted the center's "complete spectrum of cancer research," the overall quality of research programs was described as "outstanding to excellent."

"The center has developed a solid record of important discoveries in basic, translational, population-based and clinical research," said the NCI. "The strong cancer focus, substantial institutional commitment, and sustained high level of research funding base with a significant number of multi-investigator, team-based programmatic grants have positively influenced the research programs at the center. Clinical translational research has expanded with an increased number of patients enrolled on therapeutic and non-therapeutic clinical trials along with an increased number of investigator-initiated, institutional clinical trials."

Current grant funding to UCSF investigators for cancer research projects from all sources totals more than $246 million annually. This total includes funding from the NCI as well as from other areas of the NIH, the American Cancer Society and other agencies and industry partners. Since 2007, the Helen Diller Family Comprehensive Cancer Center has had a 22 percent increase in NCI funding.

The center provides patient care at four San Francisco medical centers: UCSF Medical Center at Mount Zion; UCSF Medical Center at Parnassus; San Francisco General Hospital; and the San Francisco Veterans Affairs Medical Center.

In 2015, a 289-bed children's, women's and cancer hospital complex will open in the San Francisco Mission Bay neighborhood.

The cancer center secured a gift of $150 million from an anonymous donor in 2007 at the time, it was the largest gift in UCSF's history. The center has nearly $176 million in cancer-related endowments, and $82 million for department chairs and professorships. Since 2007, 10 new endowed cancer-related chairs have been established.

In 2009, UCSF opened the Helen Diller Family Cancer Research Building, a state-of-the-art research facility housing scientists investigating cancer's basic biological mechanisms, including brain tumors, urologic oncology, pediatric oncology, cancer population sciences and computational biology.


Contact: Elizabeth Fernandez
University of California - San Francisco

Related medicine news :

1. Multiple sclerosis drug may one day treat colorectal cancer
2. Brief Life Expectancy Should Rule Out Certain Cancer Screenings: Study
3. US Drug Watchdog Now Urges Family Members Mourning The Loss Of A Loved One Who Developed Bladder Cancer After Using The Diabetes Drug Actos To Call The Johnson Law Group
4. ARUP Laboratories Introduces Blood Test to Aid in the Early Detection of Lung Cancer
5. Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
6. Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy
7. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
8. Keeping Fit May Boost Survival With Endometrial Cancer
9. First study of Oregons Hmong reveals surprising influences on cancer screenings
10. U.S. Cancer Death Rates Continue to Fall: Report
11. US cancer death rates continue to decline, national report finds
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: